Sequence Comparison 'A'

Page 2

CC under expression of the polypeptides or the expression of inactive
CC polypeptides). The nucleic acids and the polypeptides they encode may be
CC used according to standard gene therapy protocols, to treat diseases
CC associated with inappropriate TANGO expression by supplementing a
CC patients own production of the polypeptide of to rectify mutations that
CC may result in expression of an abnormally active polypeptide. The
CC polypeptides may also be used to identify and produce agonists and
CC antagonists of TANGO expression and activity which may be used to
CC modulate TANGO related processes and diseases. The polypeptides are
CC particularly useful for use as antigens for producing antibodies to TANGO
CC proteins which may be used for inhibiting the activity of TANGO proteins.
CC They may also be used to detect and quantify the presence of TANGO
CC proteins in samples and therefore identify patients in whom the protein
CC is over- or under-expressed. This sequence represents the human TANGO 184
CC protein described in the method of the invention
XX
SQ Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 3; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60

Qy         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120

Qy        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180

Qy        181 LQVQEQRKSVFDRHVVLS 198
              ||||||||||||||||||
Db        181 LQVQEQRKSVFDRHVVLS 198
```

RESULT 2
AAY66762
ID AAY66762 standard; protein; 198 AA.
XX
AC AAY66762;
XX
DT 05-APR-2000 (first entry)
XX
DE Membrane-bound protein PRO1375.
XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmaceutical; receptor immunoadhesin; gene mapping.
XX
OS Homo sapiens.
XX
PN WO9963088-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US012252.
XX
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.

Sequence Comparison 'B'

PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091358P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.

Sequence Comparison 'B'

```
PR  07-JUL-1998;  98US-0091978P.
PR  07-JUL-1998;  98US-0091982P.
PR  09-JUL-1998;  98US-0092182P.
PR  10-JUL-1998;  98US-0092472P.
PR  20-JUL-1998;  98US-0093339P.
PR  30-JUL-1998;  98US-0094651P.
PR  04-AUG-1998;  98US-0095282P.
PR  04-AUG-1998;  98US-0095285P.
PR  04-AUG-1998;  98US-0095301P.
PR  04-AUG-1998;  98US-0095302P.
PR  04-AUG-1998;  98US-0095318P.
PR  04-AUG-1998;  98US-0095321P.
PR  04-AUG-1998;  98US-0095325P.
PR  10-AUG-1998;  98US-0095916P.
PR  10-AUG-1998;  98US-0095929P.
PR  10-AUG-1998;  98US-0096012P.
PR  11-AUG-1998;  98US-0096143P.
PR  11-AUG-1998;  98US-0096146P.
PR  12-AUG-1998;  98US-0096329P.
PR  17-AUG-1998;  98US-0096757P.
PR  17-AUG-1998;  98US-0096766P.
PR  17-AUG-1998;  98US-0096768P.
PR  17-AUG-1998;  98US-0096773P.
PR  17-AUG-1998;  98US-0096791P.
PR  17-AUG-1998;  98US-0096867P.
PR  17-AUG-1998;  98US-0096891P.
PR  17-AUG-1998;  98US-0096894P.
PR  17-AUG-1998;  98US-0096895P.
PR  17-AUG-1998;  98US-0096897P.
PR  18-AUG-1998;  98US-0096949P.
PR  18-AUG-1998;  98US-0096950P.
PR  18-AUG-1998;  98US-0096959P.
PR  18-AUG-1998;  98US-0096960P.
PR  18-AUG-1998;  98US-0097022P.
PR  19-AUG-1998;  98US-0097141P.
PR  20-AUG-1998;  98US-0097218P.
PR  24-AUG-1998;  98US-0097661P.
PR  26-AUG-1998;  98US-0097951P.
PR  26-AUG-1998;  98US-0097952P.
PR  26-AUG-1998;  98US-0097954P.
PR  26-AUG-1998;  98US-0097955P.
PR  26-AUG-1998;  98US-0097971P.
PR  26-AUG-1998;  98US-0097974P.
PR  26-AUG-1998;  98US-0097978P.
PR  26-AUG-1998;  98US-0097979P.
PR  26-AUG-1998;  98US-0097986P.
PR  26-AUG-1998;  98US-0098014P.
PR  31-AUG-1998;  98US-0098525P.
PR  16-SEP-1998;  98US-0100634P.
PR  12-JAN-1999;  99US-0115565P.
XX
PA  (GETH ) GENENTECH INC.
XX
PI  Baker K,  Chen J,  Goddard A,  Gurney AL,  Smith V,  Watanabe CK;
PI  Wood WI,  Yuan J;
XX
DR  WPI; 2000-072883/06.
DR  N-PSDB; AAZ65108.
XX
PT  Membrane-bound proteins and related nucleotide sequences.
XX
PS  Claim 12; Fig 300; 822pp; English.
XX
CC  The invention provides membrane-bound PRO polypeptides and
CC  polynucleotides encoding them. The PRO sequences of the invention were
CC  identified based on extracellular domain homology screening. The PRO
CC  sequences have homology with proteins including LDL receptors, TIE
CC  ligands and various enzymes. The membrane-bound proteins and receptor
CC  molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC  immunoadhesins, for instance, can be used as therapeutic agents to block
CC  receptor-ligand interactions. The membrane-bound proteins can also be
CC  employed for screening of potential peptide or small molecule inhibitors
CC  of the relevant receptor/ligand interaction. The PRO encoding sequences
CC  are useful as hybridization probes, in chromosome and gene mapping and in
CC  the generation of antisense RNA and DNA. PRO nucleic acid sequences will
CC  also be useful for the preparation of PRO polypeptides, especially by
CC  recombinant techniques
XX
SQ  Sequence 198 AA;

  Query Match             100.0%;  Score 1031;  DB 3;  Length 198;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-104;
  Matches  198;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60

Qy         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120

Qy        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180

Qy        181 LQVQEQRKSVFDRHVVLS 198
              ||||||||||||||||||
Db        181 LQVQEQRKSVFDRHVVLS 198
```

Sequence Comparison 'C'

```
RESULT 3
AAY87231
ID  AAY87231 standard; protein; 198 AA.
XX
AC  AAY87231;
XX
DT  11-MAY-2000  (first entry)
XX
DE  Human signal peptide containing protein HSPP-8 SEQ ID NO:8.
XX
KW  Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW  inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW  antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;
KW  antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW  reproductive disorder; developmental disorder; arteriosclerosis;
KW  cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW  asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW  Parkinson's disease; Huntington's diseases; ovulatory defect;
KW  muscular dystrophy.
XX
OS  Homo sapiens.
XX
PN  WO200000610-A2.
XX
PD  06-JAN-2000.
XX
PF  25-JUN-1999;  99WO-US014484.
XX
PR  26-JUN-1998;  98US-0090762P.
PR  31-JUL-1998;  98US-0094983P.
PR  01-OCT-1998;  98US-0102686P.
PR  11-DEC-1998;  98US-0112129P.
XX
PA  (INCY-) INCYTE PHARM INC.
XX
PI  Lal P,  Tang YT,  Gorgone GA,  Corley NC,  Guegler KJ,  Baughn MR;
PI  Akerblom IE,  Au-Young J,  Yue H,  Patterson C,  Reddy R,  Hillman JL;
PI  Bandman O;
XX
DR  WPI; 2000-160673/14.
DR  N-PSDB; AAZ98116.
XX
PT  New human signal peptide-containing proteins useful in treatment,
PT  prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT  disease.
```

See page 4

Sequence Comparison 'C'

```
XX
PS   Claim 1; Page 165; 327pp; English.
XX
CC   AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC   human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
CC   anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC   neuroprotective, cardiovascular and antiasthmatic activities, and can be
CC   used in gene therapy. HSPPs can be used to treat or prevent disorders
CC   associated with decreased activity or function of HSPP. Antagonists of
CC   HSPP are used to treat or prevent disorders associated with increased
CC   activity or function of HSPP. Such diseases include cell proliferation
CC   (including cancer), inflammation, cardiovascular, neurological,
CC   reproductive or developmental disorders, (e.g. arteriosclerosis,
CC   cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC   asthma, Crohn's disease, microbial or other infections, congestive or
CC   ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC   diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
CC   nucleic acids can be used for the recombinant production of HSPP, for
CC   detecting HSPP in standard hybridisation and amplification assays (for
CC   diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC   or ribozyme therapeutics, for detecting related sequences or genetic
CC   variations, and for chromosomal mapping. HSPP are also used to raise
CC   specific antibodies (Ab) and to screen for agonists and antagonists
CC   (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP
CC   -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC   competitive drug screens, and for purification of HSPP from natural
CC   sources
XX
SQ   Sequence 198 AA;

  Query Match             100.0%;  Score 1031;  DB 3;  Length 198;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-104;
  Matches  198;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60

Qy         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120

Qy        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180

Qy        181 LQVQEQRKSVFDRHVVLS 198
              ||||||||||||||||||
Db        181 LQVQEQRKSVFDRHVVLS 198
```

Sequence Comparison 'D'

```
RESULT 4
AAY78807
ID   AAY78807 standard; protein; 198 AA.
XX
AC   AAY78807;
XX
DT   09-MAY-2000  (first entry)
XX
DE   Hydrophobic domain containing protein clone HP10529 protein sequence.
XX
KW   Hydrophobic domain; clone HP10529; nutritional supplement; SCID; HIV;
KW   cell proliferation; immune stimulant; immune deficiency; tumour; pain;
KW   rheumatoid arthritis; insulin dependent diabetes mellitus; fertility;
KW   myasthenia gravis; haematopoiesis regulator; tissue growth; depression;
KW   anti-inflammatory; infection; bodily characteristic.
XX
OS   Homo sapiens.
XX
PN   WO200000506-A2.
XX
PD   06-JAN-2000.
XX
PF   18-JUN-1999;   99WO-JP003242.
XX
PR   26-JUN-1998;   98JP-00180008.
XX
PA   (SAGA ) SAGAMI CHEM RES CENT.
PA   (PROT-) PROTEGENE INC.
XX
PI   Kato S,  Kimura T;
XX
DR   WPI; 2000-160665/14.
DR   N-PSDB; AAZ90044, AAZ90054.
XX
PT   Novel human proteins having hydrophobic domains used for research and
PT   diagnostic purposes.
XX
PS   Claim 1; Page 79-80; 117pp; English.
XX
CC   This sequence represents the hydrophobic domain containing protein, clone
CC   HP10529 protein sequence. The sequence is isolated from a human
CC   osteosarcoma cell line Soas-2. The invention relates to human proteins
CC   with hydrophobic domains, the DNA and the cDNA encoding them. The
CC   polynucleotides and proteins are predicted to have biological activities
CC   which make them suitable for treating, preventing or ameliorating medical
CC   conditions in humans and animals. Suggested activities include
CC   nutritional activity (nutritional source or supplement); cytokine and
CC   cell proliferation/differentiation activity; immune stimulating (e.g. as
CC   vaccines) or suppressing activity (e.g. to treat various immune
CC   deficiencies such as SCIDS or HIV, connective tissue disease, systemic
CC   lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary
CC   inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin
CC   dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease
CC   and autoimmune inflammatory eye disease, as well as asthma, allergies and
CC   organ transplantation); haematopoiesis regulating activity (e.g. in
CC   treatment of myeloid or lymphoid cell deficiencies); tissue growth
CC   activity (e.g. wound healing and tissue repair, ulcers, burns,
CC   periodontal disease); activin/inhibin activity; chemotactic/chemokinetic
CC   activity; haemostatic and thrombolytic activity (e.g. treating
CC   haemophilias); receptor/ligand activity; anti-inflammatory activity; and
CC   tumour inhibition activity. The polynucleotides are also stated to be
CC   useful for gene therapy. Other activities include inhibiting infections
CC   caused by bacteria, fungi, viruses and other parasites (e.g. Hepatitis,
CC   malaria); effecting bodily characteristics such as, e.g. weight, colour,
CC   skin, effecting biorhythms or caricadic cycles; enhancing fertility;
CC   treatment of depression; treatment of pain; hormonal or endocrine
CC   activity. The polynucleotides may also be used for recombinant expression
CC   of the protein
XX
SQ   Sequence 198 AA;

  Query Match             100.0%;  Score 1031;  DB 3;  Length 198;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-104;
  Matches  198;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60

Qy         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120

Qy        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180

Qy        181 LQVQEQRKSVFDRHVVLS 198
              ||||||||||||||||||
Db        181 LQVQEQRKSVFDRHVVLS 198


RESULT 5
AAM93740
ID   AAM93740 standard; protein; 198 AA.
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 15, 2004, 08:19:27 ; Search time 60 Seconds
(without alignments)
932.407 Million cell updates/sec

Title: US-09-997-573-418
Perfect score: 1031
Sequence: 1 MATLWGGLLRLGSLLSLSCL.....WKLQVQEQRKSVFDRHVVLS 198

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1031	100.0	198	3	AAY88275	Aay88275 Human TAN
2	1031	100.0	198	3	AAY66762	Aay66762 Membrane-
3	1031	100.0	198	3	AAY87231	Aay87231 Human sig
4	1031	100.0	198	3	AAY78807	Aay78807 Hydrophob
5	1031	100.0	198	4	AAM93740	Aam93740 Human pol
6	1031	100.0	198	4	AAB50966	Aab50966 Human PRO
7	1031	100.0	198	4	AAB20120	Aab20120 Human imm
8	1031	100.0	198	4	AAM38735	Aam38735 Human pol
9	1031	100.0	198	4	AAB50926	Aab50926 Human PRO
10	1031	100.0	198	4	AAB65285	Aab65285 Human PRO
11	1031	100.0	198	5	ABP61428	Abp61428 Human NF-
12	1031	100.0	198	6	ABU58100	Abu58100 Human PRO
13	1031	100.0	198	6	ABU59178	Abu59178 Novel hum
14	1031	100.0	198	6	ABU82690	Abu82690 Human sec
15	1031	100.0	198	6	ABU60609	Abu60609 Human sec
16	1031	100.0	198	6	ABU13991	Abu13991 Human PRO
17	1031	100.0	198	6	ABU72576	Abu72576 Novel hum
18	1031	100.0	198	6	ABU71432	Abu71432 Human neo
19	1031	100.0	198	6	ABU59325	Abu59325 Human sec
20	1031	100.0	198	6	ABO26022	Abo26022 Human PRO
21	1031	100.0	198	6	ABU59031	Abu59031 Human sec
22	1031	100.0	198	6	ABU92409	Abu92409 Novel hum
23	1031	100.0	198	6	ABU59474	Abu59474 Novel hum
24	1031	100.0	198	6	ABU92240	Abu92240 Novel hum
25	1031	100.0	198	6	ABU10946	Abu10946 Human PRO
26	1031	100.0	198	6	ABU81698	Abu81698 Novel hum
27	1031	100.0	198	6	ABU88637	Abu88637 Human sec
28	1031	100.0	198	6	ABO34151	Abo34151 Human PRO
29	1031	100.0	198	6	ADA37929	Ada37929 Human sec
30	1031	100.0	198	6	ADA21615	Ada21615 Human sec
31	1031	100.0	198	6	ADA10402	Ada10402 Human sec
32	1031	100.0	198	6	ADA17946	Ada17946 Human PRO
33	1031	100.0	198	6	ADA28054	Ada28054 Human sec
34	1031	100.0	198	6	ADA94634	Ada94634 Human sec
35	1031	100.0	198	6	ADA38859	Ada38859 Human sec
36	1031	100.0	198	6	ADA92980	Ada92980 Human sec
37	1031	100.0	198	7	ABO53237	Abo53237 Human sec
38	1031	100.0	198	7	ADA22541	Ada22541 Human sec
39	1031	100.0	198	7	ABO22607	Abo22607 Human sec
40	1031	100.0	198	7	ADA06707	Ada06707 Human sec
41	1031	100.0	198	7	ADA39400	Ada39400 Human sec
42	1031	100.0	198	7	ADB96426	Adb96426 Human PRO
43	1031	100.0	198	7	ADC57898	Adc57898 Human PRO
44	1031	100.0	198	7	ADC55262	Adc55262 Human PRO
45	1031	100.0	198	7	ADC12129	Adc12129 Human sec

ALIGNMENTS

Sequence comparison 'A'

RESULT 1
AAY88275
ID AAY88275 standard; protein; 198 AA.
XX
AC AAY88275;
XX
DT 16-OCT-2000 (first entry)
XX
DE Human TANGO 184 protein.
XX
KW TANGO 180; TANGO 181; TANGO 182; TANGO 183; TANGO 184; TANGO 185;
KW TANGO 186; TANGO 188; TANGO 189; TANGO 215; TANGO 187; human; murine;
KW secreted protein; transmembrane protein; gene therapy; vaccine;
KW diagnosis; treatment; detection.
XX
OS Homo sapiens.
XX
PN WO200018904-A2.
XX
PD 06-APR-2000.
XX
PF 30-SEP-1999; 99WO-US022817.
XX
PR 30-SEP-1998; 98US-00164220.
PR 02-OCT-1998; 98US-00164169.
XX
PA (MILL-) MILLENNIUM BIOTHERAPEUTICS INC.
XX
PI Barnes TM;
XX
DR WPI; 2000-293144/25.
DR N-PSDB; AAA39941, AAA39942.
XX
PT Isolated nucleic acids encoding TANGO polypeptides useful for preventing,
PT diagnosing and treating diseases associated with inappropriate protein
PT expression.
XX
PS Claim 9; Fig 9; 249pp; English.
XX
CC This invention describes novel human and murine nucleic acids encoding
CC TANGO polypeptides (which are either wholly secreted or transmembrane
CC proteins) which can be used for gene therapy and/or vaccination. The
CC peptides are designated TANGO 180 to TANGO 189 and TANGO 215. The nucleic
CC acids may be used to produce TANGO 180 to TANGO 189 and TANGO 215
CC polypeptides according to standard recombinant DNA methodologies. They
CC may also be used to detect and quantify the presence of TANGO nucleic
CC acids in a sample and therefore identify or diagnose diseases associated
CC with inappropriate TANGO expression (e.g. diseases related to over or

See page 2

Sequence Comparison E'

XX
AC AAM93740;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide, SEQ ID NO: 3711.
XX
KW Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS Homo sapiens.
XX
PN EP1130094-A2.
XX
PD 05-SEP-2001.
XX
PF 07-JUL-2000; 2000EP-00114089.
XX
PR 08-JUL-1999; 99JP-00194486.
PR 11-JAN-2000; 2000JP-00118774.
PR 02-MAY-2000; 2000JP-00183765.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR WPI; 2001-524255/58.
DR N-PSDB; AAK94692.
XX
PT 830 Primers useful for synthesizing full length cDNA clones and their use
PT in genetic manipulation.
XX
PS Claim 8; SEQ ID NO 3711; 1380pp + Sequence Listing; English.
XX
CC The invention relates to primers for synthesising full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been isolated
CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
CC been determined. Primers for synthesising the full length cDNA are useful
CC for clarifying the function of the protein encoded by the cDNA. The full
CC length clones were obtained by construction of full length enriched cDNA
CC libraries that were synthesised by the oligo-capping method. The primers
CC enable the production of the full length cDNA easily without any special
CC methods. The present sequence is a polypeptide encoded by a full length
CC human cDNA of the invention. Note: The sequence data for this patent did
CC not form part of the printed specification, but was obtained in CD-ROM
CC format directly from EPO
XX
SQ Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 4; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MATLWGGLLRLGSLLSLSCLALSVLLLAQLSDAAKNFEDVRCKCICPPYKENSGHIYNKN 60

Qy         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 ISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLLLYMV 120

Qy        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANVLNKVEYAQQRWK 180

Qy        181 LQVQEQRKSVFDRHVVLS 198
              ||||||||||||||||||
Db        181 LQVQEQRKSVFDRHVVLS 198
```

RESULT 6
AAB50966
ID AAB50966 standard; protein; 198 AA.

XX
AC AAB50966;
XX
DT 21-MAR-2001 (first entry)
XX
DE Human PRO1375 protein.
XX
KW Human; PRO; cytostatic; neotropic; neuroprotective; respiratory general;
KW antiinflammatory; antiangiogenic; immunosuppressive; immunostimulant;
KW PRO agonist; cancer; inflammatory disorder; immunological disorder.
XX
OS Homo sapiens.
XX
PN WO200073348-A2.
XX
PD 07-DEC-2000.
XX
PF 30-MAY-2000; 2000WO-US014941.
XX
PR 02-JUN-1999; 99WO-US012252.
PR 22-JUN-1999; 99US-0140650P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 09-DEC-1999; 99US-0170262P.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030999.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W, Kabakoff RC;
PI Shelton DL, Smith V, Watanabe CK, Wood WI;
XX
DR WPI; 2001-016509/02.
DR N-PSDB; AAC91568.
XX
PT Twenty eight nucleic acids encoding PRO polypeptides which are useful for
PT treating various tumors, e.g. breast cancer, and other inflammatory,
PT angiogenic and immunological disorders.
XX
PS Claim 31; Fig 32; 188pp; English.
XX
CC The present sequence is one of twenty eight novel PRO polypeptides. The
CC PRO polypeptides and their agonists, including antibodies, peptides, and
CC small molecule agonists, may be used to treat various tumours, e.g.,
CC cancers such as breast cancer, ovarian cancer, renal cancer, colorectal
CC cancer, uterine cancer, prostate cancer, lung cancer, bladder cancer,
CC central nervous system cancer, melanoma or leukaemia. They are also
CC useful for treating other disorders such as neuronal, glial, astrocytal,
CC hypothalamic and other glandular, macrophagal, epithelial, stromal and
CC blastocoelic disorders, and inflammatory, angiogenic and immunological
CC disorders
XX
SQ Sequence 198 AA;

Query Match 100.0%; Score 1031; DB 4; Length 198;
Best Local Similarity 100.0%; Pred. No. 1.4e-104;
Matches 198; Conservative 0; Mismatches 0; Indels 0; Gaps 0;